NICE is unable to make a recommendation on luspatercept (Reblozyl) for treating anaemia caused by beta-thalassaemia because BMS did not provide an evidence submission. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance

  • National Institute for Health and Care Excellence (NICE)